Treatment-Resistant Depression Treatment

Specialized Care for Treatment-Resistant Depression in Palm Beach Gardens

Treatment-resistant depression is one of the most frustrating and exhausting experiences a person can face. You have tried the medications your doctor recommended. You have adjusted doses, switched to different antidepressants, added therapy, and still found yourself in the same place. If that is where you are, you are not alone, and you are not out of options.

Allay Health and Wellness provides specialized treatment-resistant depression treatment from its Palm Beach Gardens clinic, serving patients from across Palm Beach County, Broward County, and South Florida. Our clinical team offers two primary options for patients with treatment-resistant depression: IV ketamine infusion therapy, which is an off-label treatment, and Spravato (esketamine), which is FDA-approved specifically for treatment-resistant depression used alongside an oral antidepressant. Treatment eligibility and individual outcomes vary, and all care begins with a thorough clinical evaluation by a licensed clinician.

What Is Treatment-Resistant Depression?

Treatment-resistant depression, often called TRD, generally refers to major depressive disorder that has not improved enough after at least two different antidepressant medications were tried at appropriate doses and for appropriate lengths of time. This does not mean the patient has failed. It means the usual treatment approach has not provided sufficient relief, and a more specialized clinical evaluation may be needed.

Depression is complex, and standard antidepressants do not work the same way for every person. Many conventional medications target serotonin, norepinephrine, or dopamine pathways, but research suggests these are not the only systems involved in mood regulation. For some patients, other pathways, including the glutamate system, may be clinically relevant. This is one reason ketamine-based treatments have received significant research attention in recent years. Patients wondering what to do if they are depressed should begin with a licensed evaluation. A qualified doctor for depression can review symptoms, treatment history, medications, and safety factors to determine what options may be appropriate.

How Spravato and IV Ketamine Differ for TRD Patients

Because both Spravato and IV ketamine are available at Allay Health and Wellness and both act on glutamate pathways, patients with treatment-resistant depression frequently ask how to weigh the two. The differences are meaningful and should be part of any clinical discussion.

• Regulatory status: Spravato is FDA-approved for TRD. IV ketamine is off-label for TRD. This is the most clinically and practically significant difference.
• Insurance coverage: Because of its FDA-approved status, Spravato may be eligible for insurance coverage through Medicare, Cigna, United Healthcare, and Aetna when medical necessity criteria are met. Off-label IV ketamine is generally not covered by most insurance plans.
• Formulation and delivery: Spravato is a nasal spray self-applied by the patient under clinical supervision. IV ketamine is administered intravenously by a licensed clinician.
• Oral antidepressant requirement: Spravato’s FDA-approved indication for TRD requires concurrent use of an oral antidepressant. IV ketamine does not have this requirement, though your clinician will assess your full medication picture regardless.
• Monitoring requirements: Both require supervised administration and post-session monitoring. Spravato’s REMS program mandates a minimum two-hour observation window per session and prohibits home dispensing. IV ketamine sessions are similarly monitored with vital sign tracking throughout.

Your clinician will discuss which option may be more appropriate based on your specific diagnosis, medication history, insurance coverage, and individual clinical factors.

Treatment-Resistant Depression Treatment Options at Allay Health and Wellness

Patients seeking treatment-resistant depression treatment may have different clinical needs, medical histories, and treatment goals. At Allay Health and Wellness, every recommendation begins with a comprehensive evaluation to determine which option may be appropriate for your situation. Depending on your diagnosis, previous treatment response, and overall health, your clinician may discuss FDA-approved Spravato, off-label IV ketamine infusion therapy, or ketamine-assisted therapy as part of an individualized care plan. Each option has different indications, monitoring requirements, and insurance considerations.

Spravato (Esketamine): FDA-Approved for Treatment-Resistant Depression

Spravato (esketamine) is an FDA-approved nasal spray with two specific approved indications:

1. Treatment-resistant depression (TRD) in adults, used alongside an oral antidepressant
2. Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior

For patients with a documented TRD diagnosis who are currently taking or willing to take an oral antidepressant, Spravato is the only FDA-approved ketamine-based treatment for their condition. This regulatory distinction matters clinically, practically, and financially. It is the reason Spravato may be covered by Medicare and major private insurers when eligibility criteria are met, while off-label IV ketamine generally is not.

Spravato is administered as a nasal spray that the patient self-applies under clinician supervision in a certified healthcare setting. It is never dispensed for home use. The FDA’s Risk Evaluation and Mitigation Strategy (REMS) program governs every aspect of how Spravato is administered, including the requirement that patients remain in the clinic for a minimum two-hour monitored observation period after each dose. During that observation window, a licensed clinician monitors blood pressure, heart rate, oxygen levels, and overall response in real time.

Known side effects that are monitored during every Spravato session include dissociation, sedation, nausea, dizziness, and temporary increases in blood pressure. These effects are expected, are temporary, and are actively managed by our clinical staff during and after each session.

A standard Spravato induction course involves two sessions per week for four weeks, followed by tapering to a maintenance schedule based on clinical response. The specific plan is individualized by your clinician based on how you are responding.

IV Ketamine Infusion Therapy for Treatment-Resistant Depression (Off-Label)

IV ketamine infusion therapy for depression is an off-label use of ketamine. The FDA has not specifically approved IV ketamine infusions for treatment-resistant depression or any other mental health condition. Off-label prescribing by licensed clinicians is a legal and widely practiced standard in medicine, and the body of published research examining IV ketamine for TRD continues to develop.

Like esketamine, IV ketamine acts on the brain’s glutamate system through NMDA receptor modulation. This mechanism differs from conventional antidepressants that primarily target serotonin, norepinephrine, or dopamine pathways. By influencing glutamate signaling, ketamine may support neuroplasticity processes involved in mood regulation. Some research suggests that certain patients may notice changes in depressive symptoms sooner than with standard antidepressants, although individual responses vary and no specific outcome is guaranteed. How long any benefit may last also differs from person to person, which is why ongoing clinical follow-up and individualized treatment planning are important.

At Allay Health and Wellness, IV ketamine is administered slowly through an intravenous line in a private, medically supervised treatment room. A licensed clinician remains present throughout each infusion while vital signs are monitored continuously.

Ketamine-Assisted Therapy for Treatment-Resistant Depression

For patients whose treatment-resistant depression is connected to unresolved trauma, chronic stress, or complex psychosocial history, the infusion itself may be most effective when paired with structured clinical support before and after sessions. Our ketamine-assisted therapy in Florida program combines supervised IV ketamine infusions with preparation and integration work delivered by licensed clinicians.

Who May Be a Candidate for Treatment-Resistant Depression Treatment

A thorough clinical evaluation is required before any treatment recommendation is made. Candidacy for Spravato and off-label IV ketamine shares several common criteria but also has important differences.

For Spravato (FDA-approved TRD indication):

• Formal diagnosis of treatment-resistant depression
• Documented history of inadequate response to at least two oral antidepressants at adequate doses and durations
• Current use of or willingness to use an oral antidepressant alongside Spravato
• Absence of medical contraindications, including uncontrolled hypertension, history of aneurysmal vascular disease, active psychosis, or certain other conditions

For off-label IV ketamine:

• Formal diagnosis of a depressive disorder that has not responded adequately to prior treatment
• Absence of relevant medical contraindications
• Individual clinical factors, including cardiovascular health, medication interactions, and psychiatric history

For both:

• Substance use history is evaluated carefully because ketamine is a Schedule III controlled substance under federal law. A history of substance use disorders does not automatically disqualify a patient, but it is a significant factor in the clinical assessment.

Not every patient who presents for treatment-resistant depression treatment will be an appropriate candidate. Our team does not recommend treatment when the clinical picture does not support it.

Insurance Coverage for Treatment-Resistant Depression Treatment in Florida

Understanding insurance is an important part of planning treatment-resistant depression treatment. Coverage depends on the type of treatment recommended, your diagnosis, medical necessity, and the details of your individual insurance plan. At Allay Health and Wellness, we help patients understand these factors before treatment begins by verifying benefits, explaining expected costs, and answering insurance-related questions. Our goal is to provide clear information so patients can make informed decisions without unexpected financial surprises.

Insurance coverage differs between Spravato and IV ketamine. Because Spravato is FDA-approved for treatment-resistant depression when used with an oral antidepressant, it may be eligible for coverage through Medicare Part B, Cigna, United Healthcare, and Aetna when medical necessity requirements are met. Our team assists with benefit verification, prior authorization, required documentation, and appeals when appropriate. IV ketamine infusion therapy, however, is generally prescribed off-label for depression and is not covered by most insurance plans. Every policy is different, so coverage is never guaranteed. Before beginning treatment-resistant depression treatment, our staff reviews your benefits and provides a clear explanation of your anticipated costs and available options.

Risks and Side Effects of TRD Treatment at Allay Health and Wellness

Every patient at Allay Health and Wellness receives full risk disclosure before any treatment begins. The following side effects are documented and expected:

• Dissociation: A temporary altered state involving changes in perception of time, space, or self. This is an expected and well-documented effect of both IV ketamine and Spravato at therapeutic doses. It is monitored by clinical staff throughout every session and typically resolves before discharge.
• Sedation: Both treatments produce sedation. Patients may not drive on the day of any session. A responsible adult must arrange transportation home after every appointment.
• Blood pressure changes: Temporary increases in blood pressure are common during both IV ketamine infusions and Spravato sessions. Vital signs are checked before, during, and after every session.
• Nausea and dizziness: Generally mild and typically resolving within the post-session observation period.
• Psychological effects during sessions: Some patients experience anxiety, heightened emotional intensity, or unusual perceptions. Clinical staff are present throughout every session and are trained to provide support.
• Controlled substance considerations: Ketamine is a Schedule III controlled substance under federal law. Dependency risk at supervised therapeutic doses is considered low but is not zero. This is discussed directly and honestly with every patient during intake.

Individual risk profiles vary. All patients undergo a thorough risk assessment during the intake evaluation before any treatment begins.

Treatment-Resistant Depression Treatment Locations Across Florida

Patients seeking treatment-resistant depression treatment often want access to experienced care without traveling far from home. Allay Health and Wellness is located in Palm Beach Gardens and welcomes patients from communities throughout South Florida. Many individuals travel from West Palm Beach, Jupiter, North Palm Beach, Riviera Beach, Royal Palm Beach, Lake Park, Palm Springs, Juno Beach, Delray Beach, Deerfield Beach, and surrounding areas for specialized evaluation and medically supervised care.

Although our clinic serves a wide geographic area, every patient receives the same individualized approach. We begin with a comprehensive clinical evaluation that reviews diagnosis, previous treatments, medications, medical history, and safety considerations before discussing available treatment options. Whether you are exploring IV ketamine, Spravato, or other specialized services, our goal is to provide clear guidance based on your individual needs rather than a one-size-fits-all approach. If you are looking for treatment-resistant depression treatment, our Palm Beach Gardens location offers convenient access for patients across Palm Beach and Broward Counties while maintaining consistent standards of clinical care, patient education, and ongoing follow-up.

Why Patients with Treatment-Resistant Depression Choose Allay Health and Wellness

Choosing the right provider for treatment-resistant depression treatment involves more than selecting the closest clinic. Patients often look for experience, transparent communication, individualized evaluations, and a team that follows established medical standards. At Allay Health and Wellness, we have served South Florida for more than eight years, helping patients explore specialized treatment options after conventional depression therapies have not provided sufficient improvement.

Our multidisciplinary team includes experienced medical and mental health professionals who work together to evaluate each patient’s unique clinical situation. Every recommendation begins with a thorough review of diagnosis, treatment history, current medications, overall health, and safety considerations. We do not promise specific outcomes or recommend treatment before determining whether it may be appropriate. Throughout the process, patients receive clear explanations about available options, possible risks, expected monitoring, and follow-up care. For individuals considering treatment-resistant depression treatment, our focus is on evidence-informed care, patient safety, and helping each person understand the next appropriate step in their treatment journey.

FAQs about Treatment-Resistant Depression Treatment

Q1. What makes depression treatment-resistant?
Treatment-resistant depression generally means major depressive disorder has not improved enough after at least two antidepressants were tried at appropriate doses and durations. A clinician reviews medication history, symptoms, and documentation before recommending treatment-resistant depression treatment.

Q2. Is Spravato or IV ketamine better for treatment-resistant depression?
There is no single best option for every patient. Spravato is FDA-approved for TRD, while IV ketamine is off-label. A clinician compares diagnosis, history, safety, coverage, and treatment-resistant depression treatment goals.

Q3. How quickly might treatment-resistant depression treatment produce results?
Some patients report changes during early sessions, while others improve gradually. Individual response varies, and no timeline or outcome is guaranteed. Progress is monitored with structured clinical assessments.

Q4. Do I have to stop my current antidepressants?
Not always. Spravato for TRD is used with an oral antidepressant. For IV ketamine, your clinician reviews current medications and decides whether any changes are clinically appropriate.

Q5. Will insurance cover treatment-resistant depression treatment at Allay?
Spravato may be covered by Medicare, Cigna, United Healthcare, or Aetna when requirements are met. Off-label IV ketamine is generally not covered. Benefits are verified before treatment.

Q6. How many sessions are typically needed?
Spravato often begins twice weekly for four weeks, then moves to maintenance. IV ketamine commonly starts with six infusions over two to three weeks. Plans vary individually.

Q7. Can I drive myself home after treatment?
No. Spravato and IV ketamine may cause temporary sedation or dissociation. Patients should not drive after sessions and must arrange safe transportation home with a responsible adult.

Q8. What if treatment does not work for me?
Not every patient responds. If symptoms do not improve enough, your clinician reviews progress and discusses next steps, including medication changes, referrals, or other treatment-resistant depression treatment options.

Schedule Your Consultation for Treatment-Resistant Depression Treatment

If you have tried multiple antidepressants without finding lasting relief and want to speak with a clinical team that will evaluate your situation honestly and thoroughly, Allay Health and Wellness is ready to help you take the next step.

Allay Health and Wellness
11000 Prosperity Farms Rd, Suite 101
Palm Beach Gardens, FL 33410
Email: [email protected]
Phone: (561) 421-6444

Contact us to request a free consultation. Our team will verify your insurance benefits, answer your clinical questions, and schedule your evaluation at a time that works for you. We serve patients from West Palm Beach, Jupiter, North Palm Beach, Riviera Beach, Royal Palm Beach, Lake Park, Palm Springs, Juno Beach, Stuart, Boca Raton, Delray Beach, Deerfield Beach, and communities across Palm Beach and Broward Counties.

Medical Disclaimer: The information on this page is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Spravato (esketamine) is FDA-approved for treatment-resistant depression (used with an oral antidepressant) and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior only. It is not approved for PTSD, chronic pain, anxiety, or any other condition. IV ketamine infusion therapy for treatment-resistant depression is an off-label use of ketamine and has not been specifically approved by the FDA for this condition. Individual treatment outcomes vary and are not guaranteed. All treatments at Allay Health and Wellness are provided only after evaluation and approval by a licensed clinician. Ketamine is a Schedule III controlled substance administered exclusively under medical supervision in a licensed clinical setting. Spravato is available only through certified healthcare settings under the FDA REMS program. Viewing this page does not establish a provider-patient relationship.

Reviewed by Nicholas Marino, MBA, Co-Founder and CEO, Allay Health and Wellness